Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Cytotoxic effects of flurbiprofen on rat adipose-derived stem cells.

Zeng J., Zhang X., Long L., Tan B., Zhong M., Yang F.

Animal Study on Osteoarthritis, Chronic Inflammation, published in Xenobiotica (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Xenobiotica (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40878889
DOI
10.1080/00498254.2025.2552250

Abstract (original English)

Adipose-derived stem cells (ADSCs) offer a novel approach for treating orthopaedic diseases. Flurbiprofen is a non-steroidal anti-inflammatory analgesic drug used in bone injury therapy. However, its cytotoxicity to ADSCs remains unclear.The differentiation potential of ADSCs was analysed in vitro using the differentiation induction method. Microscopic analysis, Live/Dead staining, MTT assay, and CCK8 assay were used to determine the cytotoxic effects of flurbiprofen on ADSCs at different concentration gradients. Vascular endothelial growth factor (VEGF) levels were measured by ELISA to reflect flurbiprofen's effects on the activity and paracrine function of ADSCs. ANOVA was applied, with p < 0.05 considered significant and p < 0.01 highly significant.Live cell concentration decreased dose-dependently with flurbiprofen treatment, particularly on the 7th day. The level of VEGF decreased significantly with the increase of the concentration of flurbiprofen in a certain concentration range, which indicated that flurbiprofen could inhibit the activity and secreted proteins of ADSCs.Our study showed that small doses of flurbiprofen did not affect the secretion of proteins by cells and cell activity. Therefore, it is necessary to pay attention to the concentration of flurbiprofen in the clinical application of ADSCs therapy for orthopaedic diseases.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
FlurbiprofenAnimalsRatsStem CellsVascular Endothelial Growth Factor AAdipose TissueCell DifferentiationAnti-Inflammatory Agents, Non-Steroidal

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research